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Practice points
• Phantom limb pain (PLP) is very common among amputees, with up to 85% of concerned people beginning to
feel intense neuropathic pain in the missing limb rapidly after the amputation time.
• Pharmacological treatments are commonly used to treat PLP in a first line of management, but their efficacy
remains limited.
• Most of the patients are refractory to pharmacological treatments and are often in favor of testing other
noninvasive and nonpharmacological approaches.
• Complementary and alternative medicine therapies can be helpful for the reduction of PLP.
• The very high medication administered in first and second or sometimes third intentions often alters significantly
the physical and mental state of the patient.
• As chronic pain affects the whole person (body, mind and spirit), the complementary and alternative medicine
therapies in combination with more traditional therapies can allow the patients to take care of themselves at
multiple levels and to actively participate in their own healing process and wellbeing.
• Each patient could eventually receive a combination of conventional and alternative therapies according to their
own pain.
• Progress in understanding the pathophysiological mechanisms will also allow to develop new procedures to
precisely identify this type of pain and thus implement complementary interventions or treatments.
• It is crucial to continue this type of research that requires multidisciplinary teams to effectively follow overall
patient care and to define a ‘personalized therapeutic plan’ to better help these patients with extreme suffering.
Aim: Limb amputation traumatically alters body image. Sensations rapidly prevail that the limb is still
present and 85% of patients portray phantom limb pain. Throughout the testimonies of amputated pa-
tients with intense phantom limb pain, we show the difficulty in treating this chronic pain with current
pharmacological and nonpharmacological therapies. Patients & methods: We qualitatively analyzed the
therapeutic choices of five amputees, the effectiveness of the treatments chosen and the impact on pa-
tients’ quality-of-life. Results & conclusion: In general, patients who are refractory to pharmacological
treatments are in favor of trying alternative therapies. It is therefore crucial to design a combined and
personalized therapeutic plan under the coordination of a multidisciplinary team for the wellbeing of the
patient.
First draft submitted: 25 May 2018; Accepted for publication: 16 August 2018; Published online:
3 September 2018
Keywords: chronic pain • complementary and alternative medicine therapies • neuropathic pain • phantom limb
pain • pharmacological therapies • postamputation pain • rehabilitation • therapy
Chronic pain is defined to be persistent for a longer period than expected and that can be refractory to classical
treatments [1]. Chronic low back pain, headache, fibromyalgia, neuropathic pain and central pain syndromes are
common clinical syndromes in patients suffering from chronic pain. The high prevalence of patients with chronic
pain such as neuropathic (7–10%) is due to the modest efficiency of the commonly used medication including
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opioids and nonsteroidal anti-inflammatory drugs. The effects of these drugs remain largely subjective, as one
patient may respond and another may not [2,3]. The lack of efficiency surrounding chronic pain mechanisms is also
not yet clearly defined and this indeed prevents the identification of specific target molecules. People affected by
chronic pain have highly altered quality-of-life in consequence to sleep disturbances, anxiety and depression and
this is a growing problem in our society as demonstrated by the global epidemic of opioid abuse [3–5]. Patients are
often so desperate that they go from doctor to doctor trying to find a new treatment solution adapted to their pain.
Moreover, they try to relieve their pain by using alternative therapies and this has been reported for many years [6].
Phantom limb pain (PLP) is part of neuropathic pain that is precisely defined as a pain caused by a lesion
or disease of the somatosensory system and associated with the perception of touch, pressure, pain, temperature,
position, movement and vibration [3]. PLP commonly arises from an injury to the peripheral nervous system.
Lesions of the peripheral nerves or the CNS, which are typically caused by a brachial-plexus avulsion or paraplegia,
can also cause PLP [7]. The misrepresented sensations that are behind this peripheral nerve damage likely originates
from inappropriate signaling from the peripheral neuron to its second-order targets, with multifactorial errors in
both transduction and transmission pathways of the pain signal [8,9].
As previously mentioned, the peripheral nerve system has been shown to be implicated in the development of
PLP [10,11]. This observation has been controversial, as studies have indicated that additional mechanisms involving
the CNS must exist [12–14]. Robust studies indicate that the CNS is involved in the development of the PLP
with an evident structural reorganization of the spinal cord as well as the primary somatosensory cortex after
peripheral nerve damage like in the case of an amputation [15–18]. Flor et al. contributed largely to show that
PLP is attributed to many mechanisms, including spinal plasticity [7] or cortical remapping [19,20]. Neuroimaging
studies have been readily useful for patients with peripheral neuropathies to highlight the multiple changes in
activity and functional connections that can occur in the regions of the brain that are involved in pain processing
and pain modulation [9,21,22]. From the site of amputation, receptors called nociceptors send signals to the spinal
cord (transduction) and then to the brain (transmission) where the pain is treated (perception) (Figure 1). Central
mechanisms underlying the evolution from a phantom sensation to phantom pain are localized within either the
brain or the spinal cord. At the brain level, those mechanisms consist principally in the reorganization of the
somatosensory cortex by invasion of the region of the brain (homunculus diagram, Figure 1), representing the
missing limb by neighboring areas of the somatosensory and motor cortex [23,24]. The spinal cord, which is the
connection site between the injured site (amputation) and the brain, will also be reorganized and resensitized by
loss of the afferent signal from the peripheral nerves. Peripheral mechanisms are triggered by the primary lesion of
the nerves at the site of injury that are no longer able to transmit a correct afferent nerve input to the spinal cord
and stimulate subsequent formation of a hypersensitive neuroma [25]. Nevertheless, a recent review of neuroimaging
studies has shown that evidence for a link between cortical reorganization and pain in amputees or in patients with
spinal cord injury is limited and controversial. Better standardized studies are, therefore, essential in the future to
better understand this relationship [26].
PLP is very common among amputees, with up to 85% of concerned people who begin to feel pain in the
missing limb rapidly after the amputation [27,28]. It has been evaluated that PLP can appear within 1 week after
amputation in the majority of patients, but half of the patients will experience PLP during the first 24 h after
the operation [14]. This high heterogeneity in the PLP mechanisms as previously described has the consequence
of multiple treatment possibilities [25]. PLP is considered as an important healthcare problem due to the growing
number of patients with amputations that subsequently develop other pathologies such as obesity, cardiovascular
disease and sleep disorder among others. A study published in 2008 showed that there were about 1.6 million
people with limb loss in the USA and this number was estimated to more than double to approximately 3.6 million
in 2050 [29]. Jensen et al. have evaluated the average pain intensity according to the Visual Analog Scale (VAS) to
5.3 out of 10 in a study. The pain has been shown to increase over time for 50% of patients with the other 50% of
patients reporting no change in pain intensity over time. The patients described their pain as shooting, shocking,
burning, electrical-like sensations, cramping or dysesthesia like itching or tingling, as well as nonpainful sensations,
several days per month [3,30]. The reason why some patients develop PLP after amputation and some patients do
not is still largely unknown. Several factors seem to be associated with the development of this chronic pain that
includes peripheral, central and psychological factors interacting with each other [14,27].
Pharmacological treatments are commonly used to treat PLP in a first line of management, but although many
treatment modalities such as botulinum neurotoxins, nonsteroidal anti-inflammatory drugs, opioids, tricyclic an-
tidepressants (inhibition of serotonin-norepinephrine uptake blockade, N-methyl-d-aspartate receptor antagonism
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Figure 1. Schematic representation of the pain-signaling pathway. Diagram showing the sites of action of different categories of
pharmacologic and nonpharmacologic treatments, as well as their potential in the modulation of pain between the peripheral nervous
system and CNS (brain and spinal cord). From the site of injury, such as an amputation, nociceptors send signals to the spinal cord
(transduction) and then to the brain (transmission) through the ascending pathways where the pain is treated (perception). Pain signal is
then modulated through the descending pathways. On the left hand side of the figures are mentioned the different parts of the human
body that are implicated in the pain pathway from the site of injury to the homunculus in the brain via the spinal cord. On the right hand
side of the diagram, the different options among pharmacological and nonpharmacological treatments are listed as well as their known
sites of action along the signaling pain pathway.
NSAID: Non-steroidal anti-inflammatory drug; TENS: Transcutaneous electrical nerve stimulation.
and sodium channel blockade), anticonvulsants, N-methyl-d-aspartate receptor antagonists, local anesthetics or
calcitonin have been proposed, their efficacy remains limited [14,31–36]. Already in 1980, it has been postulated that
as many as 43 treatments were used to manage PLP and since almost 40 years, the list of treatment possibilities
such as drugs, surgery and alternative therapies has not finished to grow [37].
In the search of new emerging pharmacological agents indicated in this therapeutic field, cannabis-based drugs
have been shown to be effective pharmacologic agents for treating pain through many randomized and controlled
clinical trials [38]. Despite an intense controversial debate, medical marijuana is now commonly used in clinics for
patients with chronic pain around the world [39]. Medical benefits of cannabis-derived compounds, like marijuana
have been demonstrated. However, the health risks from the use of marijuana, as many other drugs still exist and
clinical physicians, as well as patients should be well informed and aware about the practical implication of medical
marijuana both at the scientific and legal levels [40]. The pathway and discussions toward medical legalization of
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Figure 2. Evaluation of pain intensity. Evaluation of pain intensity (visual analog scale) 24 h before the beginning of
therapy sessions by electrical stimulation was done for the two patients who participated in the study under the
EPIONE protocol. The 3-month study period was divided into a 3-week baseline phase (control measures), a 9-week
therapy phase with electrical stimulation sessions three-times per week, a 1-week period for evaluation of the
outcome and, finally, a follow-up period to assess the long-term effect of the therapy. At each session during the
successive phases of the protocol, patients 1 and 2 were asked to score their highest experienced pain level before the
session using the software platform (A). The intensity of pain (from severe pain to no pain, red bar) was estimated for
each patient according to their respective testimonies, as well as the impact of pharmacological (black bars) or
nonpharmacological treatments (blue bars) on their pain relief (B).
VAS: Visual analog scale.
marijuana are important when we know that patients receiving medical marijuana reported that they were able to
reduce or stop opioids that still lead to death by overdoses [41].
For nonpharmacological treatments, several approaches are used as invasive or noninvasive treatments for
managing pain [42]. Complementary and alternative medicine therapies (CAM) can be helpful for the reduction of
PLP and include many methods such as direct intraneural stimulation, acupuncture, massage of the residual limb,
mirror box therapy, biofeedback, transcutaneous electrical nerve stimulation, treatment by electrochocs, repetitive
transcranial magnetic stimulation, virtual reality (VR)/augmented reality (AR), mental imagery, hypnotic imagery,
vibration therapy, musical therapy, as well as use of prosthesis.
Several studies have shown promise for hypnotherapy but only based on individual cases. There is an obvious need
for controlled and randomized trials to confirm the efficacy of this therapy for PLP reduction. As was mentioned
earlier, psychological, peripheral and central neural factors should help to explain the mechanism of phantom pain
that still remain uncertain. Hypnosis is one of the therapy options that can change the perception of pain by directly
targeting the psychological and emotional components of the pain [43].
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Figure 3. Therapeutic choices of five patients with neuropathic/phantom pain among the currently available pharmacologic and
nonpharmacologic treatments. The diagram illustrates the vast therapy options that could be proposed to patients suffering from
phantom limb pain. Among those different therapeutic strategies, the five patients have been treated according to conventional
pharmacologic agents, such as anti-inflammatory, opioids and anticonvulsants drugs (black letters on the left). Currently available
nonpharmacologic treatments (blue letters) to combine with the pharmacologic options are listed on the right and therapeutic options
commonly tested by the five patients are highlighted.
Another alternative therapy is emerging today with acupuncture. More and more patients are currently trying
this treatment due to the low incidence of side effects in comparison to pharmacologic treatments or invasive
approaches. It has been shown that the mechanism of action of acupuncture on chronic pain is related to both
the CNS and peripheral nervous system by brain neural activity modulation and endogenous factor release,
respectively [44]. Despite the increasing use of acupuncture worldwide in clinics, its efficiency for treating chronic
pain is still uncertain due to the poor study design. More recently, promising approaches directly derived from the
mirror therapy are the treatments based on AR/VR that are offering a more immersive experience for the amputees.
However, a literature review of these new techniques showed that higher quality studies are needed to demonstrate
their efficiency [45].
By focusing on the testimony of five different patients from our institution who suffer from intense and sometimes
untolerable phantom pain, we provide an overview of their therapeutic choices among the wide range of existing
therapeutic options that are constantly in development in order to challenge the status-quo in the PLP treatment.
We also discuss the importance of the therapeutic management by the medical staff in a multidisciplinary team.
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Figure 4. Study end points for a natural sensory feedback by transcutaneous electrical stimulations in amputee
patients. One part of the European EPIONE project is based on a noninvasive approach of transcutaneous electrical
stimulations in order to create nonpainful sensations to the amputated patient suffering from phantom limb pain (A)
and therefore alleviate the pain intensity by restoring neuroplastic changes in the cortex (B). A software platform was
developed in order to quantitatively and qualitatively follow the effect of the therapy on the painful and nonpainful
phantom limb sensations, as well as the psychological state of the patients through multiple questionnaires (C).
VAS: Visual analog scale.
Patients & methods
The study has described experiences of five patients with known conditions. The study has used the COREQ
checklist for this purpose. Patient interviews were carried out as part of a Federal Maturity project of a high school
student and were at the hospital and in two medical offices. Two of five patients (one male, one female) were
participating in parallel in a European clinical study (EPIONE, NCT02569918), on the hospital site and accepted
to participate in the interviews in accordance with the ethical standards of the regional committee on human
experimentation and with the Helsinki Declaration of 2013. The male student followed three other amputees with
neuropathic pain during their consultations in medical offices with their respective treating male physicians. Patients
were asked to participate in interviews in a prior consultation several weeks before and were asked specifically if a
student could be present. Prior to the study, three patient relationships to the interviewer were that of the primary
care physician to patient, and for two patients that of surgeon to patient. All of the interview sessions were conducted
446 Pain Manag. (2018) 8(6) future science group
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Figure 5. Chronic pain management. To assure that the patient suffering from chronic pain has an optimal and
personalized therapeutic plan, a specialist’s network is needed with the patient in the center. At the center of the
figure and directly linked to the patient is the referring specialist who is responsible to maintain the main therapeutic
plan, as well as the discussion network in the multidisciplinary specialists team potentially involved in the pain
management whatever the moment or the evolution of the pain.
with the patient consent in presence of a doctor with the specific purpose of the interview to acquire knowledge
from their personal therapeutic pathway.
Five patients (one upper limb- [female], three lower limb-amputees [two males, one female] and one patient [male]
with a plexus brachial lesion) were evaluated for their participation to extensive interviews about the therapeutic
experiences they have chosen for managing/treating their PLP to provide data for review. The interviews of the full
five patients were regulated under the State Ethics regulations, which allow five case reports.
A patient with an upper limb-amputation (female) and a patient with a plexus brachial lesion (male) had also been
included in a European multicenter study involving eight different countries implicated at clinical, industrial and
academic levels (http://project-epione.eu/) as they met the inclusion criteria. Each patient provided their consent
to participate in this aforementioned study. By applying electrical stimulation at the surface of the stump during
a period of 3 months for therapy sessions, the hypothesis was to help relieve the pain by training the brain that
the missing limb is still there. The interviews for the two patients were based on questionnaires for pain evaluation
such as VAS [46] and Brief Pain Inventory [47] standards in accordance with the ethical regulation. They are classified
as semistructured interviews according to qualitative medical research in order to collect appropriate information
about the patient [48]. The main points discussed during the interviews with the patients concerned the causes of
the disease (accident, disease), the history of amputation and the existence of postoperative rehabilitation period
(when, where, how long). The patients were asked in more details about the appearance of PLP (when, how,
intensity) and which type of treatment has been organized by the doctors and by the patient for the management
of pain. The impact of the different treatments that have been applied was also evaluated by each patient as well as
their long-term efficiency.
The three other patients who did not meet the inclusion criteria participated in the intensive interview only and
were audio recorded during a 30-min period. Interviews were discussed with each patient after summaries were
written for the report.
future science group www.futuremedicine.com 447
Case Series Flahaut, Laurent, Michetti et al.
Results
Following the testimonies of the interviewed patients, we analyzed their therapeutic choices and effectiveness of
these treatments on their phantom limb/neuropathic pain taking all the information together in order to assess the
complexity of therapies available to put forth an optimal care pathway.
Patient #1
Patient #1 was a 48-year-old woman with a distal transradial amputation of the right hand. PLP appeared a few
days after the amputation and was described as a warm sensation of itching and/or tingling. She was able to
partially imagine her phantom hand with some fingers, and particularly the middle finger, which she was unable
to unfold. She had not used a functional prosthesis regularly, but had experienced use of prosthesis in the past
during rehabilitation periods without any success nor in relation to operating the prosthesis, nor in relation to
pain reduction. She took analgesics daily and opioid pain medication such as Tramal™ (Grünenthal Pharma AG,
Switzerland). Moreover, the patient tried mirror therapy, which failed to reduce pain. She reported every day an
intense PLP (7–8/10 on the VAS) that was stronger in the evening and at night, therefore disrupting her regular
sleep patterns. She accepted to participate in the EPIONE noninvasive study. During 3 months, she came three-
times per week to the hospital to receive the therapy based on surface electrical stimulations for 1 h per session.
During the last month, therapy was applied with the introduction of hand prosthesis. Unfortunately, the patient
did not feel like there had been a significant change in pain intensity, frequency or type; however, she reported
having an improved sensation in the fingers. As such, she felt her phantom limb as more vivid, more clearly defined,
and she described this as a positive outcome for herself. The change in the pain intensity as shown in Figure 2A was
significant with a VAS score of 7.5 at the beginning of the first phase and 4.5 at the end of the therapy phase. At the
end of the study, she was able to open her phantom hand almost completely and to feel all the fingers in contrast to
the beginning of the study. Thereafter, she tried muscular electrostimulation without any success. Unfortunately,
several months after the end of the study without continued therapy her phantom fingers fell back to their initial
position and sensation (Pers. Comm. from E. D’Anna).
Patient #2
Patient #2 was a 36-year-old man who suffered from a brachial plexus injury of the left shoulder. Since the accident,
the patient felt an intense burning pain at the level of his left hand. His forearm was also partially paralyzed and
sometimes he experienced severe pain in his elbow and shoulder. The neuropathic pain was characterized mainly as
electrical shocks or stress points in addition to intense burning sensation. Since his accident, his quality-of-life had
been considerably impaired not only due to the high level of neuropathic pain but also by the use of high doses
of medication. He received the maximum daily dose of the anti-epileptic drug, Lyrica™ (Pfizer PFE Switzerland
GmbH, Zürich, Switzerland) that is commonly used for neuropathic pain. Before Lyrica, he had taken other
medication that left him comatose. He was then asked by his physician to participate in the EPIONE noninvasive
study. Unfortunately, his pain was found to increase during treatment (Figure 2A) and he started to feel electric
shocks more frequently. At the end of the follow-up, which represented 4 weeks after end of therapy by electrical
stimulation, the frequency of electrical shocks was restored to the same level that he experienced before entering
the study. In addition, his pain remained very high. After discussion with an occupational therapist, he decided to
begin vibration therapy and he has become highly interested and motivated to use neurofeedback therapy as well
as hypnotherapy.
Patient #3
Patient #3 was a 53-year-old woman who has a left leg amputation. The patient was not able to identify the exact
time when the phantom pain appeared due to high doses of prescribed anti-inflammatory drugs, morphine and
anticonvulsants, which altered her feeling of pain. Moreover, she was unable to distinguish the phantom pain
from the postoperative pain of the stump. The patient frequently experienced noninvasive therapies such as mirror
therapy and hypnosis, where the latter was considered effective in reducing pain. The patient described an acute
localized pain without warning or progression in the intensity. She was able to say precisely that she felt intense
pain within a toe, under the soles of the feet or under the heel. She says: "The only thing I can say is that the pain
comes in a violent and unexpected way. We can be discussing now and in a second, I am bent in two, crying. You
are not warned: you are shopping, and you are suddenly screaming in the middle of the shop, without any alert
when it would be happening. It is simply there and it is too late. We cannot do anything. It is precisely localized.
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I can say exactly where I hurt." The different drugs have had no effect on the intensity of the phantom pain and
the patient definitively stopped them. Each patient can be very different and therefore pain intensity or sensation
is subjective. This particular patient does not feel itching or burning but she has felt her foot as if it is there again
and completely blocked in the prosthesis. It was never comfortable. She describes her foot like a cramp mixed with
a burn.
Patient #4
Patient #4 was a 66-year-old man who lost his left leg. Like for many patients experiencing an amputation, the
phantom pain appeared only a few days after the amputation intervention. Immediately after surgery, the patient
received various drugs such as morphine to relieve postoperative pain. He quickly decided to stop morphine
because he was completely against this kind of medication. When the pain was attributed to neuropathic pain by
the doctors, antiepileptic drugs such as Lyrica were administered to the patient, but he again refused to take them,
thinking that it would have no effect on his pain. The phantom pain was really agonizing and highly impaired the
quality of sleep with only 1 h of sleep per night for long periods of time. The patient described his pain either like
a tingling or like an intense pain along his leg as if a truck was rolling over him or as if his leg was clenched in a
vice. He spent a long period at the hospital and many therapies had been proposed to him but none really showed
effectiveness. In contrast, these therapies generally accentuated the intensity of the pain, which greatly discouraged
the patient. During the rehabilitation period, the patient tried different strategies to relieve the pain, especially
muscular electrostimulation without any success. He also tried acupuncture and experienced more intense pain.
The only therapy he tested which had a positive effect on his pain was hypnosis therapy, but unfortunately that was
not reimbursed by the insurance company and he was forced to stop treatment due to the economic impact. At
one point, he expressed a desperate message: "either you do something or I will hang myself." He was then directed
to a pain center where he first received intense medication that gave no improvement. Thereafter, the medical staff
proposed spinal cord stimulation that consisted of the implantation of a stimulator under the skin in the back,
which would be able to transmit low electrical current to the spinal cord. This method is known to treat chronic
pain [49]. The patient refused to test this technology arguing that a friend had already tried it with no benefit.
Since this point, he regularly had called the ‘faiseurs de secret’, magnetizers and psychotherapists who had finally but
transiently relieved the pain. He has tried to find the best solution for him and to live with this pain in peace.
Patient #5
Patient #5 was a 44-year-old male patient with a right leg amputation. The phantom pain was felt 3-days
postamputation and appeared first like a tingling but the pain became more and more intense the following days
and weeks. He had the terrible feeling that someone was twisting his leg, and at other times, he felt that his foot
was compressed in a ski boot. The patient began to receive increasing doses of antianalgesic medication to prevent
the pain from reaching an intolerable threshold and also to provide the patient with a better quality of sleep. He
tried rapidly to combine hypnosis and mirror therapy. Pain clearly decreased during the hypnosis sessions but was
still present after. In general, the patient felt less pain with time by receiving hypnosis as well as mirror therapy. For
mirror therapy, the patient received a treatment according to three phases: First, he was asked to look at pictures
of limbs corresponding to his missing one, and second he was asked to visualize the missing limb in the correct
position. Third, he tried mirror therapy sessions during which he could see the reflexion of his intact limb in
the mirror and so he could make his brain believe that his missing limb was still there. High concentration from
the patient was required for this technique whose efficiency is highly subjective. However, for this patient mirror
therapy has been shown to be effective in reducing pain, but it did not make it disappear. The pain he felt at the
beginning like a twist or a compression became a lighter feeling with a foot in a normal position and wrapped in
a cotton bed. Lately, the pain level is ‘liveable’ but the patient is still under the control of high medication. The
patient had also expressed that it was the help of his son taking his first steps while he was at home for rehabilitation
that helps him live with his pain. These moments of everyday life have given him the force to move forward and
to combat and relativize his PLP.
Discussion
The interview experience with five different patients suffering from phantom/neuropathic pain shows us that
patients are often trying several treatment approaches without any real success in alleviating their pain. Under most
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circumstances, people with neuropathic pain suffer a major degradation of their quality-of-life and consequently
of their daily activities in relation with sleeping, mobility, working and personal interactions.
After a first-line pharmacological management of the pain, patients chose therapies not only in agreement with
their doctor but also in relation to their confidence in one method or another. The panel of pharmacological and
nonpharmacological treatments that are offered in general to these patients is very large and each treatment is
able to act at different levels along the pain-signaling pathway (Figures 1 & 3). There is obviously not a single or
combined consensus treatment. The patients discussed in this paper suffer greatly from their pain, and are often
subjected to high doses of medication that can render them nonfunctional to live normally, or even be in a comatose
state. Very often, the alternative and complementary therapies remain combined with pharmacological treatments.
Compliance of the patient is very important and depends highly in the confidence in a technique and trust for
the doctor. These treatments require regularity (number of visits, duration of visits, personalized exercises) and will
demonstrate little effectiveness if they are not applied precisely and, importantly, if not supervised by a competent
therapist. Patients with neuropathic pain should have regular clinical follow-up as the response to treatment can be
subjective to the mental/psychological state of the patient.
International groups work to develop guidelines for the pharmacologic management of neuropathic pain accord-
ing to results obtained from clinical studies, but it seems very difficult to decide a consensus-based pharmacologic
treatment for patients that are supported for neuropathic pain, as well as for other chronic pain [50]. A high
number of studies described in the review of Cliff Richardson in 2017 have tried to demonstrate the potential of
pharmacological compounds against PLP following an amputation or a nerve injury with either effectiveness on a
short-term period, or no effect or controversial effects [51]. Unfortunately, no single treatment seems to emerge even
now for these desperate patients. In general, combined pharmacological therapies are proposed to the patients with
the goal to reduce each drug independently and therefore cause fewer side effects. We had also seen that, in general,
treatments administered for the five patients interviewed in our study had only a little effect on the pain intensity
(Figure 2B). Sometimes, patients mentioned that pain was even increasing during different treatment regimens
[Pers. Comm. from Patient 4].
The use of CAM including acupuncture, hypnosis, deep-breathing exercise, massage therapy, meditation, natur-
opathy, yoga, mind–body system, dietary interventions and fasting, as well as herbal medicine has been increasing
since more than 10 years [52–57]. As chronic pain affects the whole person (body, mind and spirit), the CAM
therapies in combination with more traditional therapies could allow the patient to take care of himself at multiple
levels and to actively participate in his own healing process and wellbeing. These techniques seem to be effective in
the management of chronic pain but much remains to do to understand their mechanism of action and their true
effectiveness in the self-management of pain by the patient [44,58].
Promising technological approaches include treatments based on AR/VR that are offering a more immersive
experience for the amputees. However, a literature review of these new techniques showed that higher quality
studies are needed to demonstrate their efficiency [45]. Through a clinical study combining mirror therapy and
motor imagery including 14 upper-limb amputees who were refractory to conventional treatments for many years,
study investigators were able to demonstrate a 50% pain reduction [59]. Nevertheless, more research in the future
is needed to improve and demonstrate the potential benefit of these technologies.
We have shown with the two patients that had responded to the questionnaires that the therapy effect could be
lesion-dependent, as the two patients suffering from intense neuropathic pain did not respond in the same way.
Effectively one patient was subject to neuropathic pain following an amputation while the second patient suffered
a brachial plexus injury. However, this difference could simply be due to the many criteria that exist between two
individuals. A recent and innovative study showed that it is possible to induce referred sensations to the phantom
hand of amputees by a transcutaneous electrical nerve stimulation approach. This technique combined with the
control of bidirectional hand prosthesis allowed the patient to perform different functional tasks by a feedback
control of the sensations, but no impact on the pain was illustrated in this context of this case study [60].
Invasive treatments, such as surgical resection of neuroma, ablation of spinal cord dorsal root, thalamotomy or
sympathectomy could be proposed for patients who are completely refractory to pharmacological treatments, but
they only provide short-term improvement in PLP and are highly associated with severe complications and risk
of relapse. Other surgical procedures, like the direct spinal cord stimulation or the intracranial neurostimulation
have also been proposed but showed only a short-term relief of pain [61]. A few years ago, it has been shown
that intraneural stimulation under the control of prosthesis has been also efficient for restoring the sense of touch
in an amputee [62]. Following these previous experiments, invasive treatment based on the development of new
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technology for implantable neurostimulatory electrodes [63] that could be directly inserted in the nerves of the
stump for a direct intraneural electrical stimulation [64] has been developed. The EPIONE clinical trial included a
noninvasive intervention, which consisted in the application of surface electrical stimulations in the stump region
on referred sensation areas and therefore creating natural sensations in the missing or paralyzed limb according to
a specific stimulation program [60]. The treatment used in this specific study was based on recent evidence that
PLP may be related to neuroplastic changes in the cortex and that these changes may be modulated by providing
sensory input to the residual limb or amputation zone [65]. Figure 4 illustrates the EPIONE study as a whole.
Developing new technological and nonpharmacological solutions that will noninvasively or invasively induce
natural, meaningful sensations to the amputee represent a challenge and need to be optimized to be integrated into
routine choices for patients.
Overall, it was of interest to evaluate the evolution of alternative approaches in pain management and to show
the variety of therapies that had been and that could be proposed to a patient according to his pain characteristics
and his compliance.
Conclusion
It is important to continue multidisciplinary team research approaches to effectively follow overall patient care
and to define a ‘personalized therapeutic plan’ to better help these patients with extreme suffering (Figure 5). By
working together, varied approaches can be added to the therapeutic choices to optimize patient care. In any case,
the patient would benefit from a patient-center approach with a referring therapist in whom there is full trust.
The therapist will coordinate the medical network around the patient in order to offer a solid and personalized
therapeutic plan in agreement with individual beliefs.
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